• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Jeremy M. Sclar 2012 Irrevocable Family Trust claimed ownership of 1,617,437 shares (SEC Form 3)

    9/30/25 4:15:38 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PMN alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Jeremy M. Sclar 2012 Irrevocable Family Trust

    (Last) (First) (Middle)
    33 BOYLSTON STREET, SUITE 3000

    (Street)
    CHESTNUT HILL MA 02467

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/23/2024
    3. Issuer Name and Ticker or Trading Symbol
    ProMIS Neurosciences Inc. [ PMN ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock, no par value 1,617,437 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Warrants to Purchase Common Shares, no par value(1) 04/11/2023 04/11/2028 Common Shares 26,217 (1) D
    Warrants to Purchase Common Shares, no par value(2) 02/24/2024 02/24/2029 Common Shares 664,894 (2) D
    Tranche A Common Share Purchase Warrants(3)(4) 10/23/2024(4) (4) Common Shares 697,674 (4) D
    Tranche B Common Share Purchase Warrants(3)(5) 10/23/2024(5) (5) Common Shares 697,674 (5) D
    Tranche C Common Share Purchase Warrants(3)(6) 07/31/2024(6) (6) Common Shares 697,674 (6) D
    Explanation of Responses:
    1. Consists of 26,217 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $7.50 per whole warrant. These warrants are part of Units acquired on October 11, 2022, each consisting of one Common Share and one-quarter of one warrant to purchase one Common Share. The purchase price for each Unit was $5.40. These warrants are currently exercisable and expire on April 11, 2028, the fifth anniversary of the date the warrants first became exercisable.
    2. Consists of 664,894 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $1.75 per share. These warrants are part of Units acquired on August 24, 2023, each consisting of one Common Share and one warrant to purchase one Common Share. The purchase price for each Unit was $1.88. These warrants are currently exercisable and expire on February 24, 2029, the fifth anniversary of the date the warrants first became exercisable.
    3. On July 31, 2024, the Reporting Person acquired 697,674 units, each consisting of (a) one Common Share, (b) one Tranche A Common Share purchase warrant, (c) one Tranche B Common Share purchase warrant and (iv) one Tranche C Common Share purchase warrant, in a private placement conducted by the Issuer. The purchase price for each Unit was $2.15 per Unit.
    4. Consists of 697,674 Tranche A purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants became immediately exercisable beginning on the date that approval as was required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche A purchase warrants and the Common Shares upon the exercise thereof was received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 18 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.
    5. Consists of 697,674 Tranche B purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.02 per warrant share. These warrants became exercisable beginning on the date that such approval as was required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or any successor entity) from the shareholders of the Issuer with respect to the issuance of the Tranche B purchase warrants and the Common Shares upon the exercise thereof was received and deemed effective under Ontario law. These warrants expire on the earlier of (i) 30 months and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.
    6. Consists of 697,674 Tranche C purchase warrants, each exercisable to purchase one Common Share at an exercise price of $2.50 per warrant share. These warrants became exercisable when acquired on July 31, 2024 and expire on July 31, 2029.
    Jeremy M. Sclar 2012 Irrevocable Family Trust By: /s/ Richard A. Marks, Trustee 09/30/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PMN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Jeremy M. Sclar 2012 Irrevocable Family Trust converted options into 2,093,022 shares, increasing direct ownership by 129% to 3,710,459 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    9/30/25 4:17:04 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Jeremy M. Sclar 2012 Irrevocable Family Trust claimed ownership of 1,617,437 shares (SEC Form 3)

    3 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    9/30/25 4:15:38 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Warma Neil K

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    9/24/25 8:58:33 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    SEC Filings

    View All

    ProMIS Neurosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ProMIS Neurosciences Inc. (0001374339) (Filer)

    9/30/25 4:15:13 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by ProMIS Neurosciences Inc.

    PRE 14A - ProMIS Neurosciences Inc. (0001374339) (Filer)

    9/23/25 5:14:23 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by ProMIS Neurosciences Inc.

    EFFECT - ProMIS Neurosciences Inc. (0001374339) (Filer)

    9/11/25 12:15:27 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics

    USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Sept. 18, 2025 /PRNewswire/ -- USA News Group News Commentary –Today, Americans over 65 command $22,356 in annual healthcare spending per person versus just $4,217 for children[1], driving unprecedented investment in longevity solutions as populations worldwide confront global demographics where those aged 60+ will surge from 900 million in 2015 to 2 billion by 2050[2]. These macro forces position Avant Technologies, Inc. (OTCQB:AVAI), HCW Biologics Inc. (NASDAQ:HCWB), Solid Biosciences Inc. (NASDAQ:SLDB), ProMIS Neuorsciences, Inc. (NASDAQ:PMN), and uniQure N.V. (NASDAQ:QURE).

    9/18/25 9:10:00 AM ET
    $HCWB
    $PMN
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

    Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 128 patients, remains on track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026. Cambridge, Massachusetts, Sept. 03, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that the independent Data and Safety Monitoring Board (DSMB) for its ongoing PRECISE-AD Phase 1b clinical tri

    9/3/25 7:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

    U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer's Disease, enhancing program's potential for priority review PRECISE-AD Phase 1b Trial in Alzheimer's Disease Progressing on Schedule: Over 50% enrolled, no cases of ARIA and no patient dropouts to date Strengthened Financial Position with $21.6 Million in Gross Proceeds Raised in July 2025 Cambridge, Massachusetts, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral scleros

    8/13/25 7:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Leadership Updates

    Live Leadership Updates

    View All

    ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

    CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. "We continue to make significant progress as we are nearing completion of the Phase 1a single ascending dose clinical trial of PMN310 in Alzheimer's disease and remain on track to report top-

    5/14/24 4:01:00 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

    CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the fiscal year ended December 31, 2023 and provided a corporate update. "I am pleased to have taken the helm of ProMIS at the beginning of 2024 and am proud of the meaningful progress the team has made to date as ProMIS made the transition to a clinical deve

    4/1/24 4:15:00 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProMIS Neurosciences, Inc. Announces Leadership Transition

    CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced a strategic leadership change. The Company's Board of Directors appointed Neil Warma, a highly-qualified biotechnology industry executive and ProMIS Board member, as interim Chief Executive Officer to succeed Gail Farfel, Ph.D., who has stepped down to pursue other opportunities. Mr. Warma's appoint

    1/3/24 7:00:00 AM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

    SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/14/24 4:56:13 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ProMIS Neurosciences Inc.

    SC 13G - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/14/24 3:36:04 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ProMIS Neurosciences Inc.

    SC 13G/A - ProMIS Neurosciences Inc. (0001374339) (Subject)

    11/6/24 4:15:57 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Cashman Neil bought $14,595 worth of shares (15,000 units at $0.97) (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    2/12/25 5:21:35 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Shafmaster Madge K. bought $255,750 worth of shares (200,000 units at $1.28), increasing direct ownership by 2,400% to 208,333 units (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    9/24/24 6:56:35 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gordon Michael S bought $116,880 worth of shares (93,223 units at $1.25) (SEC Form 4)

    4 - ProMIS Neurosciences Inc. (0001374339) (Issuer)

    9/18/24 4:15:05 PM ET
    $PMN
    Biotechnology: Pharmaceutical Preparations
    Health Care